Three “leading depression experts” promote a new drug but fail to publicize their financial conflicts of interests with the company that makes this product and funded related research.

“Studies show that when research is funded by drug makers, it is significantly more likely to reach positive conclusions about effectiveness and safety of the funders’ drugs.”

“The need for transparency is paramount when the drug involved may cause serious side-effects and potential addiction.”

Read the full article here.